Robert Jeraj

List of Publications by Year
in descending order

66 papers	1,231 citations	331259 21 h-index	395343 33 g-index
67 all docs	67 docs citations	67 times ranked	2082 citing authors

#	Article	IF	Citations
1	Radiation characteristics of helical tomotherapy. Medical Physics, 2004, 31, 396-404.	1.6	185
2	Repeatability of Quantitative ¹⁸F-NaF PET: A Multicenter Study. Journal of Nuclear Medicine, 2016, 57, 1872-1879.	2.8	62
3	Interpretation and visualization techniques for deep learning models in medical imaging. Physics in Medicine and Biology, 2021, 66, 04TR01.	1.6	59
4	Technology for Innovation in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2015, 93, 485-492.	0.4	58
5	Molecular Imaging to Plan Radiotherapy and Evaluate Its Efficacy. Journal of Nuclear Medicine, 2015, 56, 1752-1765.	2.8	53
6	Diagnostic classification of solitary pulmonary nodules using dual time 18F-FDG PET/CT image texture features in granuloma-endemic regions. Scientific Reports, 2017, 7, 9370.	1.6	53
7	RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 1-1.	0.8	52
8	Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma. Radiology: Artificial Intelligence, 2020, 2, e200016.	3.0	37
9	Using neighborhood gray tone difference matrix texture features on dual time point PET/CT images to differentiate malignant from benign FDG-avid solitary pulmonary nodules. Cancer Imaging, 2019, 19, 56.	1.2	36
10	Quantitative PET in the 2020s: a roadmap. Physics in Medicine and Biology, 2021, 66, 06RM01.	1.6	36
11	Toward a standard for the evaluation of <scp>PET</scp>â€Autoâ€Segmentation methods following the recommendations of AAPM task group No. 211: Requirements and implementation. Medical Physics, 2017, 44, 4098-4111.	1.6	35
12	Imaging for Assessment of Radiation-Induced Normal Tissue Effects. International Journal of Radiation Oncology Biology Physics, 2010, 76, S140-S144.	0.4	34
13	Grand challenges for medical physics in radiation oncology. Radiotherapy and Oncology, 2020, 153, 7-14.	0.3	33
14	The role of computational methods for automating and improving clinical target volume definition. Radiotherapy and Oncology, 2020, 153, 15-25.	0.3	31
15	Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 162-8.	1.0	28
16	Dose calibration of nonconventional treatment systems applied to helical tomotherapy. Medical Physics, 2005, 32, 570-577.	1.6	27
17	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. Seminars in Nuclear Medicine, 2020, 50, 518-531.	2.5	25
18	The research versus clinical service role of medical physics. Radiotherapy and Oncology, 2015, 114, 285-288.	0.3	24

#	Article	IF	Citations
19	Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients. EJNMMI Physics, 2020, 7, 76.	1.3	24
20	RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, 1-1.	0.8	24
21	Radiomics for Identification and Prediction in Metastatic Prostate Cancer: A Review of Studies. Frontiers in Oncology, 2021, 11, 771787.	1.3	23
22	Optimizer convergence and local minima errors and their clinical importance. Physics in Medicine and Biology, 2003, 48, 2809-2827.	1.6	22
23	Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. Physics in Medicine and Biology, 2019, 64, 025017.	1.6	22
24	Spatiotemporal Stability of Cu-ATSM and FLT Positron Emission Tomography Distributions During Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 399-405.	0.4	21
25	Comparison of NaF and FDG PET/CT for Assessment of Treatment Response in Castration-Resistant Prostate Cancers With Osseous Metastases. Clinical Genitourinary Cancer, 2015, 13, e7-e17.	0.9	21
26	FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. , 2019, 7, 23.		20
27	Molecular Imaging Biomarkers of Resistance to Radiation Therapy for Spontaneous Nasal Tumors in Canines. International Journal of Radiation Oncology Biology Physics, 2015, 91, 787-795.	0.4	19
28	Comparison of 11 automated PET segmentation methods in lymphoma. Physics in Medicine and Biology, 2020, 65, 235019.	1.6	19
29	Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, LBA2010-LBA2010.	0.8	18
30	Optimal flattening filter shape of a surface brachytherapy applicator. Physics in Medicine and Biology, 2002, 47, 723-735.	1.6	13
31	Quantification of bone flare on 18F-NaF PET/CT in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 324-330.	2.0	13
32	Future of Physics in Medicine and Biology. Acta OncolÃ³gica, 2009, 48, 178-184.	0.8	11
33	Towards optimal stopping in radiation therapy. Radiotherapy and Oncology, 2019, 134, 96-100.	0.3	10
34	Optimal treatment plan adaptation using mid-treatment imaging biomarkers. Physics in Medicine and Biology, 2020, 65, 245011.	1.6	10
35	Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1857-1869.	3.3	9
36	DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 168-168.	0.8	8

#	Article	IF	Citations
37	Randomized phase III trial of concurrent chemoradiation followed by nivolumab or placebo for locally advanced non-small cell lung cancer (NSCLC) (RTOG 3505).. Journal of Clinical Oncology, 2017, 35, TPS8579-TPS8579.	0.8	7
38	Quantitative FDG PET/CT may help risk-stratify early-stage non-small cell lung cancer patients at risk for recurrence following anatomic resection. Journal of Thoracic Disease, 2019, 11, 1106-1116.	0.6	6
39	Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).. Journal of Clinical Oncology, 2013, 31, LBA2010-LBA2010.	0.8	6
40	18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen. Cancer Chemotherapy and Pharmacology, 2016, 78, 1245-1252.	1.1	4
41	Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Cancer Chemotherapy and Pharmacology, 2018, 82, 211-219.	1.1	4
42	Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687. Tomography, 2021, 7, 139-152.	0.8	4
43	Repeatability of Quantitative 18F-FET PET in Glioblastoma. Biomedical Physics and Engineering Express, 2021, 7, 035020.	0.6	3
44	Development and validation of a longitudinal soft-tissue metastatic lesion matching algorithm. Physics in Medicine and Biology, 2021, 66, 155017.	1.6	3
45	Image intensity histograms as imaging biomarkers: application to immune-related colitis. Biomedical Physics and Engineering Express, 2021, 7, 065019.	0.6	3
46	Impact of scanner harmonization on PET-based treatment response assessment in metastatic melanoma. Physics in Medicine and Biology, 2020, 65, 225003.	1.6	3
47	Probabilistic target definition and planning in patients with prostate cancer. Physics in Medicine and Biology, 2021, 66, 215011.	1.6	3
48	Impact of Anatomic Location of Bone Metastases on Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 306-314.	0.9	2
49	Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5037-5037.	0.8	2
50	Molecular and functional imaging in radiation oncology. Cancer Treatment and Research, 2008, 139, 63-95.	0.2	2
51	Quantitative Total Bone Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Using NaF PET/CT.. Journal of Clinical Oncology, 2015, 33, e16016-e16016.	0.8	1
52	Quantitative total bone imaging (QTBI) in patients with metastatic castration-resistant prostate cancer (CRPC) using NaF PET/CT.. Journal of Clinical Oncology, 2015, 33, 180-180.	0.8	1
53	Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: the CHAARTED 2 Trial: A trial of the ECOG-ACRIN Cancer Research Group (EA8153).. Journal of Clinical Oncology, 2019, 37, TPS5094-TPS5094.	0.8	1
54	Spatial process decomposition for quantitative imaging biomarkers using multiple images of varying shapes. Statistics in Medicine, 2021, 40, 1243-1261.	0.8	1

#	Article	IF	Citations
55	In reply to the letter to the editor: â€œIn reply to Fiorino et al: The central role of the radiation oncologist in the multidisciplinary and multiprofessional model of modern radiation therapyâ€• Radiotherapy and Oncology, 2021, 155, e22-e23.	0.3	0
56	Abstract 227: Association between treatment response classification and resistance in metastatic prostate cancer patients treated with enzalutamide. , 2021, , .		0
57	A pharmacodynamic trial of sequential sunitinib (Su) with bevacizumab (Bev) in patients (Pts) with renal cell carcinoma and other advanced solid malignancies.. Journal of Clinical Oncology, 2013, 31, 434-434.	0.8	0
58	Pharmacodynamic study using FLT PET/CT in patients treated with axitinib.. Journal of Clinical Oncology, 2013, 31, 2537-2537.	0.8	0
59	Pharmacodynamic (PD) assessment using FLT-PET/CT imaging in patients treated with an interrupted high-dose axitinib schedule.. Journal of Clinical Oncology, 2015, 33, 11105-11105.	0.8	0
60	Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.. Journal of Clinical Oncology, 2015, 33, TPS2601-TPS2601.	0.8	0
61	[18F]NaF PET/CT imaging biomarkers of progression-free survival in metastatic prostate cancer.. Journal of Clinical Oncology, 2016, 34, 277-277.	0.8	0
62	Validation of imaging-based biomarkers of treatment response in patients with metastatic castrate-resistant prostate cancer treated with enzalutamide.. Journal of Clinical Oncology, 2016, 34, TPS11616-TPS11616.	0.8	0
63	Correlation of FDG PET/CT heterogeneity with disease recurrence in early-stage, non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, e20049-e20049.	0.8	0
64	Pharmacodynamic phase I study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.. Journal of Clinical Oncology, 2017, 35, e14088-e14088.	0.8	0
65	Targeting differential response using molecular guided biopsies in bone-metastatic prostate cancer.. Journal of Clinical Oncology, 2019, 37, e16516-e16516.	0.8	0
66	Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141). Blood, 2020, 136, 30-31.	0.6	0